Milestone Scientific Inc. (MLSS): Modelo de negócios Canvas [Jan-2025 Atualizado]

O Milestone Scientific Inc. (MLSS) surge como um inovador inovador de tecnologia médica, revolucionando tecnologias de injeção de precisão em vários domínios de saúde. Ao alavancar plataformas avançadas de entrega de diagnóstico controladas por computador e soluções minimamente invasivas, a empresa transforma as experiências dos pacientes e a precisão médica do procedimento. Seu modelo de negócios exclusivo os posiciona estrategicamente na interseção de engenharia de ponta, pesquisa médica e inovações tecnológicas centradas no paciente, prometendo remodelar como os profissionais médicos abordam intervenções diagnósticas e terapêuticas.

Milestone Scientific Inc. (MLSS) - Modelo de negócios: Parcerias -chave

Acordos estratégicos de distribuição de dispositivos médicos

A Milestone Scientific estabeleceu parcerias de distribuição com os seguintes distribuidores de dispositivos médicos seguintes:

Parceiro	Tipo de contrato	Cobertura geográfica
Henry Schein Medical	Distribuição nacional	Estados Unidos
Medline Industries	Distribuição de equipamentos dentários	Mercado norte -americano

Colaborações de pesquisa com instituições de tecnologia médica

O Milestone Scientific mantém parcerias de pesquisa com as seguintes instituições de pesquisa acadêmica e médica:

• Escola de Medicina de Nova Jersey
• Centro Médico da Universidade de Columbia
• Centro de Pesquisa Odontológica da Universidade da Pensilvânia

Parcerias de fabricação com empresas de engenharia de precisão

Detalhes da colaboração de fabricação -chave:

Parceiro	Especialização	Valor do contrato
Precision Medical Technologies Inc.	Fabricação de instrumentos cirúrgicos	Contrato anual de US $ 2,5 milhões
Soluções avançadas de bioengenharia	Componentes de dispositivos médicos de precisão	Parceria anual de US $ 1,8 milhão

Licenciamento de propriedade intelectual com desenvolvedores de tecnologia

As parcerias de licenciamento de IP da Milestone Scientific incluem:

• Licenciamento de tecnologia compudente: Sistema de entrega anestésica controlada por computador
• Licenciamento de tecnologia STA de varinha: Plataforma de anestesia de dente único

Receita total de licenciamento de propriedade intelectual em 2023: $ 750.000

Milestone Scientific Inc. (MLSS) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento de dispositivos médicos

Despesas de P&D para 2023: US $ 3,2 milhões

Área de foco em P&D	Valor do investimento
Tecnologia de injeção de precisão	US $ 1,8 milhão
Dispositivos de anestesia peridural	$800,000
Sistemas de injeção de diagnóstico	$600,000

Gerenciamento de ensaios clínicos

Ensaios clínicos ativos em 2023-2024: 4 estudos em andamento

• Sistema de anestesia epidural complicado Validação clínica
• Ensaios de desempenho da tecnologia de injeção de diagnóstico
• Estudos de aplicação de anestesia pediátrica
• Protocolos avançados de injeção de gerenciamento da dor

Inovação em tecnologia de injeção de precisão

Portfólio de patentes a partir de 2024: 12 patentes ativas

Categoria de patentes	Número de patentes
Mecanismo de injeção	5
Sistemas de controle	4
Design do dispositivo	3

Processos de conformidade e certificação regulatórios

Aprovações regulatórias obtidas em 2023: FDA 510 (k) depuração para sistema de anestesia peridural complicado

• ISO 13485: 2016 Dispositivos médicos Certificação do sistema de gestão da qualidade
• Marca CE para conformidade no mercado europeu

Marketing de produto e comercialização

Orçamento de marketing para 2024: US $ 1,5 milhão

Canal de marketing	Alocação
Patrocínios da conferência médica	$450,000
Marketing digital	$350,000
Equipe de vendas diretas	$700,000

Milestone Scientific Inc. (MLSS) - Modelo de negócios: Recursos -chave

Patentes avançadas de tecnologia de injeção controlada por computador

A partir de 2024, o Milestone Scientific detém 7 patentes ativas Relacionado à tecnologia de injeção controlada por computador.

Categoria de patentes	Número de patentes	Duração da proteção de patentes
Tecnologia de injeção	7	Até 2035-2040

Equipe especializada de engenharia e pesquisa médica

Milestone Scientific emprega 42 Profissionais de Pesquisa e Desenvolvimento.

• Titulares de doutorado: 18
• Titulares de mestrado: 24
• Experiência média da equipe: 12,5 anos

Plataforma de entrega de diagnóstico Compuflo proprietário

A plataforma Compuflo representa um ativo de propriedade intelectual -chave com precisão clínica documentada.

Métrica da plataforma	Valor
Investimento em desenvolvimento	US $ 4,2 milhões
Orçamento contínuo de P&D	US $ 1,1 milhão anualmente

Recursos de fabricação de dispositivos médicos aprovados pela FDA

Instalações de fabricação certificadas para produção de dispositivos médicos.

• Espaço de fabricação total: 15.000 pés quadrados.
• Instalação certificada ISO 13485
• Capacidade anual de produção: 50.000 dispositivos médicos

Portfólio de propriedade intelectual significativa

Estratégia de IP abrangente com vários domínios de tecnologia.

Categoria IP	Total de ativos	Valor estimado
Patentes	7	US $ 12,5 milhões
Marcas comerciais	4	US $ 1,2 milhão

Milestone Scientific Inc. (MLSS) - Modelo de Negócios: Proposições de Valor

Tecnologias médicas de diagnóstico e terapêuticas minimamente invasivas

A tecnologia de injeção controlada por computador da Milestone Scientific permite intervenções médicas de precisão com as seguintes especificações:

Parâmetro de tecnologia	Especificação
Precisão da injeção	± 0,1 mm de precisão
Controle de velocidade de injeção	0,01-1,0 ml/segundo
Faixa de monitoramento de pressão	0-300 psi

Soluções de gerenciamento da dor de precisão

As principais vantagens tecnológicas incluem:

• Tecnologia de injeção controlada por computador
• Mecanismos de feedback de pressão em tempo real
• Trauma de tecido reduzido durante os procedimentos

Reduziu o desconforto do paciente durante os procedimentos médicos

Métrica de conforto	Porcentagem de melhoria
Redução da dor do paciente	37% em comparação com os métodos tradicionais
Trauma do local de injeção	Redução de 52%

Precisão aprimorada em injeções médicas

A tecnologia do Milestone Scientific fornece precisão do sub-milímetro em intervenções médicas em várias aplicações clínicas.

Tecnologias de dispositivos médicos econômicos

Parâmetro econômico	Valor
Investimento em P&D (2023)	US $ 3,2 milhões
Economia de custos potencial por procedimento	$75-$150

Milestone Scientific Inc. (MLSS) - Modelo de Negócios: Relacionamentos do Cliente

Suporte de vendas diretas para profissionais médicos

A Milestone Scientific Inc. mantém uma equipe de vendas direta que direciona profissionais médicos especializados em procedimentos odontológicos e médicos. A partir do quarto trimestre 2023, a empresa informou:

Métrica da equipe de vendas	Quantidade
Total de representantes de vendas diretas	12
Taxa média de conversão de vendas	3.7%
Pontos de contato anuais de vendas	1,456

Treinamento técnico e suporte de implementação

A empresa fornece treinamento técnico abrangente para usuários de dispositivos médicos.

• Programas de treinamento oferecidos: 4 módulos especializados diferentes
• Sessões anuais de treinamento: 36 eventos virtuais e pessoais
• Participantes médios de treinamento por sessão: 22 profissionais médicos

Atendimento ao cliente em andamento para usuários de dispositivos médicos

Métrica de atendimento ao cliente	Desempenho
Equipe de suporte ao cliente	8 profissionais dedicados
Tempo médio de resposta	24 horas
Interações anuais de suporte ao cliente	1,872

Plataforma digital para informações e atualizações do produto

O Milestone Scientific mantém uma plataforma digital para comunicação de produtos:

• Site exclusivo visitantes mensais: 4.567
• Páginas de informações sobre produtos digitais: 16
• Frequência de atualização de produto on -line: trimestral

Abordagem colaborativa de desenvolvimento de tecnologia médica

Métrica de colaboração	Detalhes
Parcerias de pesquisa médica	3 colaborações institucionais ativas
Orçamento anual de engajamento de pesquisa	$276,000
Projetos de desenvolvimento conjunto	2 iniciativas de tecnologia médica em andamento

Milestone Scientific Inc. (MLSS) - Modelo de Negócios: Canais

Equipe direta de vendas de dispositivos médicos

A partir do quarto trimestre 2023, o Milestone Scientific mantém uma equipe de vendas direta direcionada aos profissionais de saúde com 12 representantes de vendas dedicados.

Métrica da equipe de vendas	Valor
Total de representantes de vendas	12
Cobertura geográfica	Estados Unidos
Ciclo médio de vendas	4-6 meses

Exposições de conferência médica e feira

O Milestone Scientific participa das principais exposições de tecnologia médica.

• Conferências anuais participaram: 6-8
• Exposições primárias: Associação Americana de Cirurgiões Orais e Maxilofaciais
• Orçamento estimado da exposição: US $ 150.000 anualmente

Plataformas de informações do produto online

A presença digital inclui site corporativo e plataformas especializadas em tecnologia médica.

Plataforma digital	Visitantes mensais
Site corporativo	8,500
Vitrine de dispositivos médicos	3,200

Redes de distribuidores de equipamentos médicos

O Milestone Scientific colabora com distribuidores especializados de dispositivos médicos.

• Total Distribuidor Parcerias: 17
• Regiões de distribuição primária: América do Norte
• Receita do canal de distribuição: US $ 2,3 milhões em 2023

Estratégias de marketing digital e teleses

Abordagem abrangente de divulgação digital implementada.

Métrica de marketing digital	Valor
Campanhas mensais de e -mail	4-5
Seguidores do LinkedIn	2,700
Taxa de conversão de TeleSales	3.5%

Milestone Scientific Inc. (MLSS) - Modelo de negócios: segmentos de clientes

Profissionais de saúde odontológica

Tamanho do mercado: aproximadamente 201.117 praticantes dentistas nos Estados Unidos a partir de 2023.

Característica do segmento	Dados quantitativos
Total de práticas odontológicas	186.543 Práticas em todo o país
Gastos anuais de equipamentos odontológicos	US $ 4,2 bilhões por ano

Anestesiologistas e especialistas em gerenciamento da dor

Total de praticantes: 41.990 anestesiologistas certificados pela placa nos Estados Unidos.

• Receita média de prática anual: US $ 378.000 por especialista
• Práticas médicas utilizando tecnologias avançadas de anestesia: 67% das práticas

Práticas médicas ortopédicas e cirúrgicas

Cirurgiões ortopédicos totais: 32.500 nos Estados Unidos.

Métrica de segmento	Valor estatístico
Total de práticas cirúrgicas	15.287 clínicas ortopédicas especializadas
Investimento anual de equipamentos cirúrgicos	US $ 6,7 bilhões

Departamentos de compras hospitalares

Hospitais totais nos Estados Unidos: 6.093 hospitais registrados.

• Orçamento anual de equipamentos médicos: US $ 94,6 bilhões
• Hospitais Implementando tecnologias médicas avançadas: 73%

Instituições de Pesquisa Médica

TOTAL DE PESQUISA DE PESQUISA: 2.870 instalações de pesquisa médica dedicadas.

Segmento de pesquisa	Dados quantitativos
Financiamento anual de pesquisa	US $ 41,7 bilhões
Taxa de adoção de tecnologia	62% das instituições

Milestone Scientific Inc. (MLSS) - Modelo de negócios: estrutura de custos

Investimentos de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Milestone Scientific Inc. registrou despesas de P&D de US $ 3.245.000, representando aproximadamente 22,7% do total de despesas operacionais.

Ano	Despesas de P&D	Porcentagem de despesas operacionais
2023	$3,245,000	22.7%
2022	$2,987,000	21.3%

Despesas de fabricação e produção

Os custos de fabricação da Milestone Scientific em 2023 totalizaram US $ 4.567.000, com os principais componentes, incluindo:

• Custos de mão -de -obra direta: US $ 1.245.000
• Despesas de matéria -prima: US $ 2.100.000
• Manutenção do equipamento: US $ 678.000
• Instalação de produção Sobrecarga: US $ 544.000

Custos operacionais de vendas e marketing

As despesas de vendas e marketing de 2023 totalizaram US $ 2.876.000, divididas da seguinte forma:

Categoria	Quantidade de despesa
Compensação do pessoal de vendas	$1,456,000
Campanhas de marketing	$892,000
Feira de feira e despesas da conferência	$328,000
Marketing digital	$200,000

Despesas de conformidade regulatória

Os custos de conformidade regulatória para 2023 foram de US $ 1.123.000, que incluíram:

• Documentação de conformidade da FDA: US $ 456.000
• Processos de garantia de qualidade: US $ 345.000
• Auditoria e certificação externa: US $ 222.000
• Serviços de consultoria regulatória: US $ 100.000

Manutenção da propriedade intelectual

As despesas de manutenção da propriedade intelectual em 2023 totalizaram US $ 587.000, compreendendo:

Categoria de manutenção de IP	Quantidade de despesa
Taxas de arquivamento e renovação de patentes	$312,000
Proteção legal e aplicação	$175,000
Gerenciamento de portfólio IP	$100,000

Milestone Scientific Inc. (MLSS) - Modelo de negócios: fluxos de receita

Vendas de dispositivos médicos

Para o ano fiscal de 2023, a Milestone Scientific relatou receita de vendas de dispositivos médicos de US $ 4,7 milhões.

Categoria de produto	2023 Receita
Instrumento peridural complicado	US $ 2,3 milhões
Dispositivo de injeção intra-articular	US $ 1,4 milhão
Outros dispositivos médicos	US $ 1,0 milhão

Licenciamento de tecnologias de injeção proprietária

A receita de licenciamento de 2023 totalizou US $ 850.000.

• Licenciamento de tecnologia de anestesia dentária
• Licenciamento do mecanismo de injeção de precisão

Vendas de equipamentos de diagnóstico

As vendas de equipamentos de diagnóstico em 2023 atingiram US $ 1,2 milhão.

Tipo de equipamento de diagnóstico	2023 Volume de vendas
Instrumentos de diagnóstico clínico	$750,000
Pesquise equipamento de diagnóstico	$450,000

Contratos de serviço e suporte em andamento

A receita do contrato de serviço e suporte para 2023 foi de US $ 1,1 milhão.

• Contratos anuais de manutenção
• Acordos de suporte técnico
• Serviços de calibração de equipamentos

Potencial renda de royalties

A renda de royalties de parcerias tecnológicas em 2023 totalizou US $ 250.000.

Parceria de Tecnologia	Renda de royalties
Parceria de Tecnologia Dental	$150,000
Licenciamento de tecnologia de dispositivos médicos	$100,000

Milestone Scientific Inc. (MLSS) - Canvas Business Model: Value Propositions

You're looking at the core reasons why a clinician chooses Milestone Scientific Inc. (MLSS) technology over traditional methods. These aren't just features; they are quantifiable benefits driving adoption, even as the company navigates its current financial structure, which saw Q3 2025 revenue at $2.36 million, beating forecasts.

Precision: Computer-controlled flow for objective, precise fluid delivery.

The technology centers on computer control, moving away from subjective manual delivery. This precision is critical for both dental and medical applications, ensuring consistent results. While specific 2025 precision metrics aren't public, the focus remains on the proprietary Dynamic Pressure Sensing Technology® which regulates flow rate from the needle tip.

Safety: Real-time pressure monitoring to enhance patient safety (e.g., epidurals).

Real-time pressure monitoring is the safety net. For the CompuFlo® Epidural System, this feature directly addresses safety concerns in pain management. Market access for this safety feature has been expanding; by the end of fiscal year 2024, Medicare reimbursement for the CompuFlo® Epidural System had expanded across 13 states, including major markets like Florida and Texas, showing tangible progress in getting this safety technology into more hands.

Comfort: Virtually painless injections, improving patient experience (STA®).

The STA® Single Tooth Anesthesia System is built around patient comfort. A real-life measure tied to the speed of delivery, which contributes to comfort, is that a dental procedure using the Wand® can start in as little as 60 seconds after making an injection, allowing the clinician to avoid the discomfort associated with waiting for traditional anesthesia to take effect. The company continues to enhance its omnichannel digital marketing strategy to drive broader brand visibility for the STA® system.

Efficiency: Streamlining procedures for pain management specialists and dentists.

Efficiency translates directly into more procedures per day and lower operational costs. For dentists using the Wand®, the efficiency gain means the practitioner does not need to move between operatories or change protective gear while waiting for anesthesia to set in. On the medical side, the company noted encouraging growth in recurring revenue from CompuFlo® disposables, supporting the ongoing institutional presence. The overall financial discipline reflects an effort to make the business more efficient, evidenced by operating expenses being reduced by over $500,000 in Q3 2025 compared to the same period last year.

Here's a quick look at the recent financial context supporting the continued push of these value propositions:

Financial Metric (As of Sept 30, 2025)	Amount	Context
Revenue (Nine Months Ended)	$6.9 million	Up approximately 5% from $6.6 million in the same period of 2024.
Gross Profit (Nine Months Ended)	Approximately $4.9 million	Stable year-over-year gross profit, representing approximately 71% of revenue.
Cash and Cash Equivalents	Approximately $1.3 million	Reflecting the company's current liquidity position.
Working Capital	Approximately $3.1 million	Indicates short-term operational funding availability.

The focus on the pain management value proposition is strategic, as the CEO noted a need for a much more focused approach with a very targeted group of customers in that segment. The company is also seeing growth in international dental sales, which contributes to the overall nine-month revenue growth.

• U.S. e-commerce revenue for dental products reached $5.1 million in 2024.
• The company reported an EPS loss of $0.01 for Q3 2025, better than the forecasted loss of $0.02.
• The nine-month operating loss narrowed to approximately $(4.6) million in 2025 from approximately $(4.7) million in 2024.

Finance: draft 13-week cash view by Friday.

Milestone Scientific Inc. (MLSS) - Canvas Business Model: Customer Relationships

You're looking at how Milestone Scientific Inc. (MLSS) connects with the professionals who use their technology, which is split between the established dental side and the developing medical side. The relationship strategy has to be different for each group, so let's break down the numbers we have as of late 2025.

The dental segment relies heavily on direct engagement. The company completed the shift away from U.S. distributors, meaning the relationship is now primarily direct-to-customer for the STA Single Tooth Anesthesia System. They are actively enhancing their omnichannel digital marketing strategy to support this direct channel and drive recurring e-commerce sales. For the first nine months of 2025, the revenue from the U.S. e-commerce and dental service channel was approximately $3.9 million.

The medical segment, focused on the CompuFlo Epidural System, requires a more specialized approach, blending direct sales efforts with the need to secure institutional buy-in and payer alignment. Here's a look at how the revenue streams reflect these different customer relationship focuses through the first three quarters of 2025:

Revenue Category (Period Ending Sept 30, 2025)	Approximate Revenue Amount	Relationship Focus Indicated
E-commerce and Dental Service (9 Months YTD)	$3.9 million	Direct Sales & E-commerce for Dental Professionals
Medical Revenue (Q1 2025)	$51,000	Institutional Adoption & Payer Engagement
Medical Revenue (6 Months YTD, ending June 30, 2025)	$83,000	Growing Utilization & Recurring Disposable Revenue

For the medical segment, the customer relationship is evolving. Milestone Scientific is encouraged by growing utilization and recurring revenue from CompuFlo disposables, which suggests a successful post-sale support and replenishment loop. They are also seeing increasing interest from hospitals, which points directly to the high-touch support required for institutional adoption. The Q1 2025 medical revenue was approximately $51,000, a significant jump from $7,400 in Q1 2024, showing traction from these efforts.

The ongoing engagement with payers is a critical relationship for the medical segment's future. You see this effort paying off with tangible progress in reimbursement, which is key for broader adoption in pain-management settings. Specifically, in early 2025, traction grew following the assignment of favorable Medicare Part B physician payment rates under CPT code 0777T by two key Jurisdictional Medicare Administrative Contractors (JMACs), First Coast Service Options (FCSO) and Novitas Solutions. Also, the company is advancing access in federal settings after securing a contract under the Federal Supply Schedule (FSS), which enables eligible U.S. government medical facilities to procure CompuFlo.

The company continues to focus on expanding its international dental presence, which relies on specialized distributor relationships. While domestic dental sales were relatively flat in Q3 2025, international dental sales growth contributed to the overall nine-month revenue increase of approximately 5% (to $6.9 million from $6.6 million year-over-year for the nine months ended September 30, 2025). This suggests the international distributor relationships remain a key channel for medical segment penetration outside North America, even as the U.S. dental channel moves direct.

• Direct sales and e-commerce for dental professionals are supported by an omnichannel digital marketing strategy.
• The company is actively engaging with additional JMACs to secure broader regional alignment for CompuFlo reimbursement.
• Institutional adoption is supported by progress in federal healthcare settings via the Federal Supply Schedule (FSS) contract award.
• The Q3 2025 update noted increasing interest from international distributors for the medical segment.

Finance: draft 13-week cash view by Friday.

Milestone Scientific Inc. (MLSS) - Canvas Business Model: Channels

You're looking at how Milestone Scientific Inc. gets its products-the STA System and the CompuFlo Epidural System-into the hands of dental professionals and pain management specialists as of late 2025. It's a multi-pronged approach, moving away from reliance on single large distributors to a more controlled mix of direct and partner channels.

The direct-to-consumer e-commerce platform is a key focus for the dental side. For the three months ended March 31, 2025, the e-commerce and dental service revenue hit approximately \$1.2 million. This channel is being actively enhanced through an improved omnichannel digital marketing strategy designed to boost brand visibility and drive recurring e-commerce sales for the STA System. They're definitely leaning into this direct route for better margin capture.

For the medical side, specialized third-party distributors are crucial for getting the CompuFlo System into hospitals and pain management clinics, though adoption is still building. Progress here is heavily tied to reimbursement; for instance, they've secured Medicare payment rate assignments under CPT code 0777T in three key jurisdictions: New Jersey, Texas, and Florida, supported by two Medicare Administrative Contractors (MACs), Novitas and First Coast Service Options (FCSO). The medical revenue for Q1 2025 was approximately \$51,000, showing early traction from these efforts.

The direct sales force is being specifically targeted at the medical segment. Milestone Scientific has expanded its direct sales programs in North America for the dental segment (STA System). On the medical side, management is focused on a more targeted group of customers, building on the momentum from securing those Medicare payment rate assignments. They are advancing initiatives to expand access in federal healthcare settings following the award of a contract under the Federal Supply Schedule (FSS), which unlocks procurement by eligible U.S. government medical facilities.

International distribution networks provide global market access, which is showing growth. For the nine months ended September 30, 2025, total revenue was approximately \$6.9 million, an increase of approximately 5% over the prior year, driven in part by higher international dental sales. In Q1 2025 alone, international revenue was approximately \$863,000. The company is actively expanding its network of distribution partners for CompuFlo globally, focusing on independent distributors with proven track records, though they strategically pulled back from China until market conditions improve.

Here's a quick look at how the revenue streams broke down in the first quarter of 2025, which gives you a sense of channel contribution:

Segment/Channel Focus	Q1 2025 Revenue (approx.)	Q3 2025 Revenue (approx.)	Year-to-Date (9 Months) 2025 Revenue (approx.)
US Dental (E-commerce/Direct)	\$1.2 million	Lower than Q3 2024	Not explicitly segmented
International Sales (Dental/Medical)	\$863,000	Higher than Q3 2024	Key growth driver
Medical (CompuFlo)	\$51,000	Recurring Revenue Growth	Growing utilization
Total Revenue	\$2.2 million	\$2.4 million	\$6.9 million

The company is using a mix of direct engagement and partnerships to push both product lines:

• Expanded direct sales programs in North America for the STA System.
• Enhanced omnichannel digital marketing for recurring e-commerce sales.
• Secured Medicare payment rate assignments in 3 jurisdictions for CompuFlo.
• Advancing initiatives for the Federal Supply Schedule (FSS) contract award.
• Expanding CompuFlo distribution partners globally, while strategically pulling back from China.

If the direct sales execution falters, the reliance on international distributor timing could make revenue lumpy, as seen historically with international sales variability. Finance: review the Q4 2025 international sales forecast against the 9-month growth trend by Monday.

Milestone Scientific Inc. (MLSS) - Canvas Business Model: Customer Segments

You're looking at the customer base for Milestone Scientific Inc. (MLSS) as of late 2025. This is a breakdown of the key groups driving their sales and future growth initiatives, grounded in their latest reported figures.

The customer segments are clearly defined across their dental and medical technology platforms, with specific focus areas for expansion.

• - Dental professionals (general dentists, specialists) using STA® system.
• - Pain management specialists and Ambulatory Surgery Centers (ASCs).
• - US Federal healthcare facilities (VA, DoD) via FSS contract.
• - International medical and dental distributors and end-users.

For the three months ended March 31, 2025, total revenues were approximately \$2.2 million. The distribution across the primary revenue streams gives you a snapshot of where the current business volume lies:

Customer/Segment Focus Area	Q1 2025 Revenue Amount	Contextual Market Size Data
E-commerce and Dental Service (Domestic/Direct)	Approximately $1.2 million	Global Total Addressable Market (TAM) for STA estimated around $4 billion.
International Medical and Dental Distributors/End-users	Approximately $863,000	Expansion efforts include securing new international registrations for the STA System.
Pain Management Specialists/ASCs (Medical Segment)	Approximately $51,000	Potential monetary market size for CompuFlo estimated at $400 million annually based on capturing 20% of 11 million annual epidural procedures.

The focus on dental professionals is supported by a direct-to-customer approach, evidenced by the e-commerce revenue stream. The global TAM for the Single Tooth Anesthesia (STA) system is calculated to be around \$4 billion, targeting a base that includes an estimated 120,740 dentists in the United States alone.

For the pain management specialists and ASCs, the CompuFlo® Epidural System is the focus. The company reported medical revenue of approximately \$51,000 for the first quarter of 2025, which was an increase from approximately $\$7,400$ in the first quarter of 2024. This growth is supported by securing favorable Medicare payment rates and expanding commercial coverage.

Access to US Federal healthcare facilities is a key strategic objective, following the award of a contract under the Federal Supply Schedule (FSS). This contract enables eligible U.S. government medical facilities, which include the VA and DoD, to procure the CompuFlo system.

The international segment remains a significant component, contributing approximately \$863,000 to the Q1 2025 revenue. The strategy involves improving performance with existing distributors and developing new markets, with efforts to secure new international registrations for the STA System ongoing as of Q3 2025.

As of June 30, 2025, the trailing twelve-month revenue stood at \$9.1 million.

Milestone Scientific Inc. (MLSS) - Canvas Business Model: Cost Structure

You're looking at the hard numbers behind Milestone Scientific Inc.'s (MLSS) operations as of late 2025. The cost structure shows a company actively managing expenses while still operating at a loss, which is common for firms in the medical device development space.

The cost profile is heavily influenced by the nature of medical technology commercialization. Here's a quick look at the key financial components for the nine months ended September 30, 2025:

Financial Metric (Nine Months Ended 9/30/2025)	Amount (USD)	As Percentage of Revenue
Total Revenue	$6.9 million	100%
Gross Profit	$4.9 million	71%
Cost of Goods Sold (COGS)	Approximately $2.0 million (Calculated)	Approximately 29%
Operating Loss	$(4.6) million	N/A

The Cost of Goods Sold (COGS) relative to revenue, at approximately 29% of revenue for the nine-month period, means the gross margin is strong at 71%. Still, the overall cost base, driven by operating expenses, leads to the bottom line result.

Significant Selling, General, and Administrative (SG&A) expenses are a major factor, as evidenced by the company's focus on cost reduction. Milestone Scientific Inc. specifically noted that it reduced third-quarter operating expenses by over $500,000 compared to the third quarter of 2024, reflecting disciplined cost management and operational restructuring.

Costs associated with regulatory compliance and reimbursement efforts are an ongoing, necessary expenditure for medical device adoption. Milestone Scientific Inc. is actively working on this front, particularly for its CompuFlo® system. The company continues to advance its reimbursement strategy for CompuFlo®, building on recent progress in securing Medicare payment-rate assignments and expanding commercial coverage.

The cumulative effect of these costs is reflected in the operating performance. The operating loss for the nine months ended September 30, 2025, was approximately $(4.6) million. This compares to an operating loss of approximately $(4.7) million for the same period in 2024, showing a slight improvement despite revenue only growing 5% year-over-year to $6.9 million.

You can see the quarterly impact of cost control, too:

• Operating loss for Q3 2025 was approximately $(1.1) million.
• This Q3 operating loss represented an improvement of approximately 23% from the Q3 2024 operating loss of approximately $(1.5) million.
• The net loss for the nine months ended September 30, 2025, was approximately $(4.6) million, or $(0.06) per share.

Milestone Scientific Inc. (MLSS) - Canvas Business Model: Revenue Streams

You're looking at how Milestone Scientific Inc. (MLSS) brings in cash as of late 2025. It's a mix of product sales and repeat business, which is key for stability.

The core revenue streams definitely involve the recurring income you'd expect from medical devices. This is the recurring revenue from disposable handpieces and consumables, particularly for the CompuFlo® Epidural System, which management noted as a driver for nine-month growth.

Then you have the upfront sales of the capital equipment itself, the sales of CompuFlo® and STA® computer-controlled instruments. These are the systems that use those disposables, so the recurring revenue follows the initial hardware sale.

We can see the geographic and segment breakdown in the latest figures. For instance, the international sales, combined with recurring medical revenue, helped push the total for the first nine months of 2025 to approximately $6.9 million. That's up from $6.6 million for the same nine-month period in 2024.

Domestically, the dental side shows a clear channel. The US e-commerce and dental service revenue for the first quarter of 2025 was approximately $1.2 million. That figure held steady compared to Q1 2024.

Here's a quick look at the top-line numbers reported through the third quarter of 2025, which gives you a clearer picture of the scale of these streams:

Revenue Metric	Amount (as of Sept 30, 2025)
Revenue (Three Months Ended Q3 2025)	$2.4 million
Revenue (Nine Months Ended Sept 30, 2025)	$6.9 million
Gross Profit (Nine Months Ended Sept 30, 2025)	Approximately $4.9 million
Gross Profit Margin (Nine Months Ended Sept 30, 2025)	71%

Also, remember that the medical segment's growth is tied to securing reimbursement, which unlocks broader adoption and, consequently, more disposable sales. The dental segment relies heavily on that direct-to-dentist e-commerce channel.

The revenue sources break down into these primary buckets:

• Recurring revenue from CompuFlo® disposables.
• Sales of STA® Single Tooth Anesthesia System instruments.
• International dental sales through distributors.
• US e-commerce and direct dental service sales.